| abstract |
Refers to chimeric antigen receptors that comprise an antigen-binding molecule that specifically binds to lecithin type C-1 (CLL-1), wherein the antigen-binding molecule comprises at least one of: a) a CDR1 of variable heavy chain comprising an amino acid sequence selected from the group consisting of SEQs. ID. NO: 17, 51, 73 and 95; b) a variable heavy chain CDR2 comprising an amino acid sequence selected from the group consisting of SEQs. ID. NO: 18, 52, 74 and 96; c) a variable heavy chain CDR3 comprising an amino acid sequence selected from the group consisting of SEQs. ID. NO: 19, 53, 75 and 975; d) a variable light chain CDR1 comprising an amino acid sequence selected from the group consisting of SEQs. ID. NO: 22, 56, 78 and 100; e) a variable light chain CDR2 comprising an amino acid sequence selected from the group consisting of SEQs. ID. NO: 23, 57, 79 and 101; f) a variable light chain CDR3 comprising an amino acid sequence selected from the group consisting of SEQs. ID. NO: 24, 58, 80 and 102. It also comprises at least one costimulatory domain and one activation domain. It also refers to a method of treatment against leukemia, lymphoma or myeloma, rheumatoid arthritis, psoriasis, asthma, among others. |